As of 2025-05-23, the EV/EBITDA ratio of Revance Therapeutics Inc (RVNC) is -4.67. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. RVNC's latest enterprise value is 764.47 mil USD. RVNC's TTM EBITDA according to its financial statements is -163.87 mil USD. Dividing these 2 quantities gives us the above RVNC EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 7.0x - 9.5x | 7.7x |
| Forward P/E multiples | 10.3x - 16.9x | 13.7x |
| Fair Price | (19.90) - (18.55) | (20.47) |
| Upside | -645.3% - -608.4% | -660.8% |
| Date | EV/EBITDA |